Article Type
Changed
Thu, 03/28/2019 - 14:55

 

The direct cost of treating skin diseases in the United States was almost $75 billion in 2013, according to a report on the burden of skin disease from the American Academy of Dermatology.

For the nearly 85 million Americans who were seen by a physician for a skin disease in 2013, about $45.9 billion was spent on medical costs such as office visits, procedures, and tests; $15 billion was spent on prescription drugs; and $4.1 billion went for vaccines and skin cancer screening. Another $10 billion was spent on OTC products, the AAD’s Burden of Skin Disease Work Group reported (J Am Acad Dermatol. 2017 Feb 24. doi: 10.1016/j.jaad.2016.12.043).

Looking at the largest slice of the skin disease pie – the 61% represented by medical services – the most expensive condition in 2013 was cutaneous infections at $8.1 billion, with noncancerous skin growths next at $7.0 billion and wounds and burns third with spending of $6.4 billion, the work group said.

The per-capita cost of skin disease in 2013 was $213, compared with $950 per person for cardiovascular disease, $785 for diabetes, and $147 for end-stage renal disease, they noted.

In discussing the future burden of skin disease, the work group noted that the aging U.S. population and “the increased costs of currently in-use and newly developed dermatologic treatment options [need] to be addressed by an appropriate increase in dermatologic care providers.”

Meeting/Event
Publications
Topics
Sections
Meeting/Event
Meeting/Event

 

The direct cost of treating skin diseases in the United States was almost $75 billion in 2013, according to a report on the burden of skin disease from the American Academy of Dermatology.

For the nearly 85 million Americans who were seen by a physician for a skin disease in 2013, about $45.9 billion was spent on medical costs such as office visits, procedures, and tests; $15 billion was spent on prescription drugs; and $4.1 billion went for vaccines and skin cancer screening. Another $10 billion was spent on OTC products, the AAD’s Burden of Skin Disease Work Group reported (J Am Acad Dermatol. 2017 Feb 24. doi: 10.1016/j.jaad.2016.12.043).

Looking at the largest slice of the skin disease pie – the 61% represented by medical services – the most expensive condition in 2013 was cutaneous infections at $8.1 billion, with noncancerous skin growths next at $7.0 billion and wounds and burns third with spending of $6.4 billion, the work group said.

The per-capita cost of skin disease in 2013 was $213, compared with $950 per person for cardiovascular disease, $785 for diabetes, and $147 for end-stage renal disease, they noted.

In discussing the future burden of skin disease, the work group noted that the aging U.S. population and “the increased costs of currently in-use and newly developed dermatologic treatment options [need] to be addressed by an appropriate increase in dermatologic care providers.”

 

The direct cost of treating skin diseases in the United States was almost $75 billion in 2013, according to a report on the burden of skin disease from the American Academy of Dermatology.

For the nearly 85 million Americans who were seen by a physician for a skin disease in 2013, about $45.9 billion was spent on medical costs such as office visits, procedures, and tests; $15 billion was spent on prescription drugs; and $4.1 billion went for vaccines and skin cancer screening. Another $10 billion was spent on OTC products, the AAD’s Burden of Skin Disease Work Group reported (J Am Acad Dermatol. 2017 Feb 24. doi: 10.1016/j.jaad.2016.12.043).

Looking at the largest slice of the skin disease pie – the 61% represented by medical services – the most expensive condition in 2013 was cutaneous infections at $8.1 billion, with noncancerous skin growths next at $7.0 billion and wounds and burns third with spending of $6.4 billion, the work group said.

The per-capita cost of skin disease in 2013 was $213, compared with $950 per person for cardiovascular disease, $785 for diabetes, and $147 for end-stage renal disease, they noted.

In discussing the future burden of skin disease, the work group noted that the aging U.S. population and “the increased costs of currently in-use and newly developed dermatologic treatment options [need] to be addressed by an appropriate increase in dermatologic care providers.”

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME